Published in Transplantation on January 15, 2013
Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients. Sci Transl Med (2015) 3.71
Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance. Am J Transplant (2014) 1.63
Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant (2014) 1.49
Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol (2015) 1.17
Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. J Clin Oncol (2014) 0.99
Induction of tolerance through mixed chimerism. Cold Spring Harb Perspect Med (2014) 0.97
Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J Am Soc Nephrol (2013) 0.94
Spontaneous restoration of transplantation tolerance after acute rejection. Nat Commun (2015) 0.91
Transplantation tolerance: from theory to clinic. Immunol Rev (2014) 0.88
Plasmacytoid dendritic cells: no longer an enigma and now key to transplant tolerance? Am J Transplant (2013) 0.87
Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance. Clin Pharmacol Ther (2012) 0.85
Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantation. J Transplant (2013) 0.85
The hematopoietic system in the context of regenerative medicine. Methods (2015) 0.84
Nonchimeric HLA-Identical Renal Transplant Tolerance: Regulatory Immunophenotypic/Genomic Biomarkers. Am J Transplant (2015) 0.84
Immune Tolerance for Autoimmune Disease and Cell Transplantation. Annu Rev Biomed Eng (2016) 0.83
What's new in clinical solid organ transplantation by 2013. World J Transplant (2014) 0.81
Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism. Transplantation (2013) 0.80
Hematopoietic stem cell infusion/transplantation for induction of allograft tolerance. Curr Opin Organ Transplant (2015) 0.80
Effect of ex vivo Expanded Recipient Regulatory T Cells on Hematopoietic Chimerism and Kidney Allograft Tolerance Across MHC Barriers in Cynomolgus Macaques. Transplantation (2016) 0.80
Mesenchymal stromal (stem) cells to improve solid organ transplant outcome: lessons from the initial clinical trials. Curr Opin Organ Transplant (2013) 0.79
Prospects for therapeutic tolerance in humans. Curr Opin Rheumatol (2014) 0.78
Patterns of Immune Regulation in Rhesus Macaque and Human Families. Transplant Direct (2015) 0.78
Transplantation tolerance. Pediatr Nephrol (2013) 0.78
Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplants. Blood (2016) 0.77
Tolerance signatures in transplant recipients. Curr Opin Organ Transplant (2015) 0.77
The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT. Bone Marrow Transplant (2015) 0.75
Immunomodulatory Strategies Directed Toward Tolerance of Vascularized Composite Allografts. Transplantation (2015) 0.75
Facilitating cells: Translation of hematopoietic chimerism to achieve clinical tolerance. Chimerism (2016) 0.75
Stable mixed chimerism and tolerance to human organ transplants. Chimerism (2016) 0.75
Transplant Tolerance Induction in Newborn Infants: Mechanisms, Advantages, and Potential Strategies. Front Immunol (2016) 0.75
Tolerance--is it worth it? Cold Spring Harb Perspect Med (2014) 0.75
Combining Theoretical and Experimental Techniques to Study Murine Heart Transplant Rejection. Front Immunol (2016) 0.75
Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization. JCI Insight (2016) 0.75
Limited immune tolerance induced by transient mixed chimerism. Korean J Intern Med (2015) 0.75
A novel approach to measuring cell-mediated lympholysis using quantitative flow and imaging cytometry. J Immunol Methods (2015) 0.75
The Knife's Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but With a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques. Am J Transplant (2016) 0.75
Hematopoietic stem cells and solid organ transplantation. Transplant Rev (Orlando) (2016) 0.75
B Cell Receptor Genes Associated With Tolerance Identify a Cohort of Immunosuppressed Patients With Improved Renal Allograft Graft Function. Am J Transplant (2017) 0.75
Recent Progress in Cell Therapy in Solid Organ Transplantation. Int J Organ Transplant Med (2017) 0.75
Harnessing Apoptotic Cells for Transplantation Tolerance: Current Status and Future Perspectives. Curr Transplant Rep (2017) 0.75
Actively acquired tolerance of foreign cells. Nature (1953) 19.82
IMMUNOGENETIC CONSEQUENCES OF VASCULAR ANASTOMOSES BETWEEN BOVINE TWINS. Science (1945) 12.87
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med (2012) 3.27
T cell immune reconstitution following lymphodepletion. Semin Immunol (2007) 2.35
Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A (2007) 2.27
Weaning of immunosuppression in living donor liver transplant recipients. Transplantation (2001) 2.18
Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59
Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts. Am J Transplant (2011) 1.38
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA (2012) 1.33
Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients. Ann Surg (1999) 1.24
Production of donor T cells is critical for induction of donor-specific tolerance and maintenance of chimerism. J Immunol (2004) 1.20
Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol (2012) 1.20
CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am J Transplant (2011) 1.18
Operational tolerance: past lessons and future prospects. Liver Transpl (2011) 1.14
Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol (2011) 1.12
Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr Opin Organ Transplant (2011) 1.10
Clinical operational tolerance after renal transplantation: current status and future challenges. Ann Surg (2010) 1.08
Dissociation of hemopoietic chimerism and allograft tolerance after allogeneic bone marrow transplantation. J Immunol (2001) 1.08
Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant (2005) 1.00
A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg (2000) 0.89
Donor MHC class II antigen is essential for induction of transplantation tolerance by bone marrow cells. J Immunol (2000) 0.86
The quest for transplantation tolerance: have we finally sipped from the cup? Sci Transl Med (2012) 0.85
Mixed allogeneic chimerism prevents obstructive airway disease in a rat heterotopic tracheal transplant model. J Heart Lung Transplant (1998) 0.84
Expression of MHC class II antigen is essential in tolerance induction by donor bone marrow cell in antilymphocyte serum-treated and rapamycin-treated mice. Transplant Proc (2001) 0.82
Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med (2013) 7.40
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology (2008) 3.52
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol (2009) 3.43
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med (2012) 3.27
Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg (2007) 2.67
Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res (2004) 2.50
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology (2014) 2.14
Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ Res (2006) 1.98
A comprehensive risk assessment of mortality following donation after cardiac death liver transplant - an analysis of the national registry. J Hepatol (2011) 1.94
Intrahepatic biliary cystadenoma: role of cyst fluid analysis and surgical management in the laparoscopic era. Surgery (2004) 1.89
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA (2010) 1.84
Mucosal vascular alterations in isolated small-bowel allografts: relationship to humoral sensitization. Am J Transplant (2003) 1.64
Laparoscopic liver surgery: Shifting the management of liver tumors. Hepatology (2006) 1.58
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl (2006) 1.56
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology (2012) 1.56
Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl (2010) 1.56
MRI predictors of cognitive change in a diverse and carefully characterized elderly population. Neurobiol Aging (2010) 1.56
Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment. J Exp Med (2005) 1.53
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. Am J Transplant (2011) 1.51
Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transpl (2014) 1.50
Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology (2004) 1.45
Heterogeneity of cognitive trajectories in diverse older persons. Psychol Aging (2010) 1.44
Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology (2009) 1.44
Regulation of alloimmune responses (GvH reactions) in vitro by autologous donor bone marrow cell preparation used in clinical organ transplantation. Transplantation (2002) 1.42
A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation (2002) 1.32
Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant (2005) 1.32
Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood (2006) 1.29
Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation (2003) 1.28
TNF-alpha is critical to facilitate hemopoietic stem cell engraftment and function. J Immunol (2008) 1.26
Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol (2007) 1.26
A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation (2005) 1.25
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol (2010) 1.25
Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology (2011) 1.25
Transplantation of the hand, face, and composite structures: evolution and current status. Clin Plast Surg (2007) 1.23
Waiting for organ transplantation: results of an analysis by an Institute of Medicine Committee. Biostatistics (2003) 1.23
Production of donor T cells is critical for induction of donor-specific tolerance and maintenance of chimerism. J Immunol (2004) 1.20
Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol (2013) 1.20
Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol (2009) 1.18
Extractables characterization for five materials of construction representative of packaging systems used for parenteral and ophthalmic drug products. PDA J Pharm Sci Technol (2013) 1.15
Allosensitization of islet allograft recipients. Transplantation (2007) 1.13
Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model. Transplantation (2007) 1.13
Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. Liver Transpl (2003) 1.12
Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation (2002) 1.11
Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med (2012) 1.10
Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res (2002) 1.09
Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol (2013) 1.08
Bone marrow transplantation temporarily improves pancreatic function in streptozotocin-induced diabetes: potential involvement of very small embryonic-like cells. Transplantation (2010) 1.07
CD8α+ plasmacytoid precursor DCs induce antigen-specific regulatory T cells that enhance HSC engraftment in vivo. Blood (2010) 1.07
Relation of plasma homocysteine to plasma amyloid beta levels. Neurochem Res (2006) 1.06
Flt3-ligand treatment prevents diabetes in NOD mice. Diabetes (2004) 1.06
The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation. Transplantation (2009) 1.06
The economic impact of MELD on liver transplant centers. Am J Transplant (2005) 1.05
Science of composite tissue allotransplantation. Transplantation (2008) 1.05
Retinal pigment epithelium damage enhances expression of chemoattractants and migration of bone marrow-derived stem cells. Invest Ophthalmol Vis Sci (2006) 1.04
CD45 congenic bone marrow transplantation: evidence for T cell-mediated immunity. Stem Cells (2004) 1.03
The Product Quality Research Institute (PQRI) Leachables and Extractables Working Group Initiatives for Parenteral and Ophthalmic Drug Product (PODP). PDA J Pharm Sci Technol (2013) 1.02
Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol (2008) 1.02
The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant (2005) 1.01
Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation (2007) 1.01
Stem cell-based therapeutic applications in retinal degenerative diseases. Stem Cell Rev (2011) 1.01
Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation (2005) 1.00
The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation (2004) 0.99
Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation (2004) 0.99
Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans. Transplantation (2013) 0.98
Quality of life for donors after living donor liver transplantation: a review of the literature. Liver Transpl (2010) 0.98
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl (2011) 0.97
Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol (2012) 0.96
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation (2004) 0.96
Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants. Transplantation (2015) 0.96
Evidence that FoxP3+ regulatory T cells may play a role in promoting long-term acceptance of composite tissue allotransplants. Transplantation (2011) 0.96
Graft facilitating cells are derived from hematopoietic stem cells and functionally require CD3, but are distinct from T lymphocytes. Exp Hematol (2004) 0.96
Laparoscopic liver resection. J Am Coll Surg (2005) 0.95
Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transpl Immunol (2003) 0.95
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology (2013) 0.95
Plasmacytoid dendritic cells regulate autoreactive B cell activation via soluble factors and in a cell-to-cell contact manner. J Immunol (2009) 0.95
Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney Int (2012) 0.94
Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J Am Soc Nephrol (2013) 0.94
A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation (2004) 0.94
Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury. Basic Res Cardiol (2012) 0.93
Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation (2011) 0.93
Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. Transplantation (2003) 0.93